

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600rkb

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right

Truncation

NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:43:27 ON 17 SEP 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:43:46 ON 17 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2003 HIGHEST RN 586945-00-8

DICTIONARY FILE UPDATES: 16 SEP 2003 HIGHEST RN 586945-00-8

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s glycyrrhizin

L1 72 GLYCYRRHIZIN

=> s glycyrrhizinic

L2 12 GLYCYRRHIZINIC

=> s famotidine

L3 5 FAMOTIDINE

=> file caplus uspatful biosis scisearch europatfull

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
----------------------	------------	-------

	ENTRY	SESSION
FULL ESTIMATED COST	13.06	13.27

FILE 'CAPLUS' ENTERED AT 09:44:24 ON 17 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:44:24 ON 17 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:44:24 ON 17 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'SCISEARCH' ENTERED AT 09:44:24 ON 17 SEP 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'EUROPATFULL' ENTERED AT 09:44:24 ON 17 SEP 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

```
=> s ll
L4          4605 L1
```

=> s 12
L5 3299 L2

$$\Rightarrow s \quad l_3$$

$$L_6 \quad 4653 \quad L_3$$

```
=> s l1 and l2
L7          3226 L1 AND L2
```

```
=> s 17 and 16
L8      10 L7 AND L6'
```

=> d 18 1-10 abs bib

L8 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AB Title compns., useful for treatment of gastric ulcer, acute gastritis,
etc., contain (A) stomachic agents, (B) histamine H2 receptor antagonists
and/or proton pump inhibitors, and optionally (C) mucous membrane
repairing agents and antacid agents. Thus, tablets contg. famotidine,
anise ext., aldioxa, and synthetic hydrotalcite showed strong
deodorization effect on bad mouth odor in volunteers.

AN 2003:559026 CAPLUS

DN 139:111674

TI Pharmaceutical compositions for treatment of bad mouth odor and gastric mucosal injury

IN Nishihara, Toru; Kawaguchi, Makoto

PA Rohto Pharmaceutical Co., Ltd., Japan

50 Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Country	Year	Population (millions)	Urban population (millions)	Urban population (%)	Population density (per sq km)	Urban population density (per sq km)	Population growth rate (%)	Urban population growth rate (%)	Population growth rate (%)	Urban population growth rate (%)	Population growth rate (%)	Urban population growth rate (%)
Algeria	1980	10.0	4.0	40.0	100	400	1.5	2.5	1.5	2.5	1.5	2.5
Algeria	1985	10.5	4.5	42.9	105	450	1.8	2.8	1.8	2.8	1.8	2.8
Algeria	1990	11.0	5.0	45.5	110	500	2.0	3.0	2.0	3.0	2.0	3.0
Algeria	1995	11.5	5.5	47.8	115	550	2.2	3.2	2.2	3.2	2.2	3.2
Algeria	2000	12.0	6.0	50.0	120	600	2.5	3.5	2.5	3.5	2.5	3.5
Algeria	2005	12.5	6.5	52.0	125	650	2.8	3.8	2.8	3.8	2.8	3.8
Algeria	2010	13.0	7.0	53.8	130	700	3.0	4.0	3.0	4.0	3.0	4.0
Algeria	2015	13.5	7.5	55.6	135	750	3.2	4.2	3.2	4.2	3.2	4.2
Algeria	2020	14.0	8.0	57.1	140	800	3.5	4.5	3.5	4.5	3.5	4.5
Algeria	2025	14.5	8.5	58.6	145	850	3.8	4.8	3.8	4.8	3.8	4.8
Algeria	2030	15.0	9.0	60.0	150	900	4.0	5.0	4.0	5.0	4.0	5.0
Algeria	2035	15.5	9.5	61.3	155	950	4.2	5.2	4.2	5.2	4.2	5.2
Algeria	2040	16.0	10.0	62.5	160	1000	4.5	5.5	4.5	5.5	4.5	5.5
Algeria	2045	16.5	10.5	63.6	165	1050	4.8	5.8	4.8	5.8	4.8	5.8
Algeria	2050	17.0	11.0	64.7	170	1100	5.0	6.0	5.0	6.0	5.0	6.0
Algeria	2055	17.5	11.5	65.7	175	1150	5.2	6.2	5.2	6.2	5.2	6.2
Algeria	2060	18.0	12.0	66.7	180	1200	5.5	6.5	5.5	6.5	5.5	6.5
Algeria	2065	18.5	12.5	67.6	185	1250	5.8	6.8	5.8	6.8	5.8	6.8
Algeria	2070	19.0	13.0	68.4	190	1300	6.0	7.0	6.0	7.0	6.0	7.0
Algeria	2075	19.5	13.5	69.2	195	1350	6.2	7.2	6.2	7.2	6.2	7.2
Algeria	2080	20.0	14.0	70.0	200	1400	6.5	7.5	6.5	7.5	6.5	7.5
Algeria	2085	20.5	14.5	70.7	205	1450	6.8	7.8	6.8	7.8	6.8	7.8
Algeria	2090	21.0	15.0	71.4	210	1500	7.0	8.0	7.0	8.0	7.0	8.0
Algeria	2095	21.5	15.5	72.1	215	1550	7.2	8.2	7.2	8.2	7.2	8.2
Algeria	2100	22.0	16.0	72.7	220	1600	7.5	8.5	7.5	8.5	7.5	8.5
Algeria	2105	22.5	16.5	73.3	225	1650	7.8	8.8	7.8	8.8	7.8	8.8
Algeria	2110	23.0	17.0	73.9	230	1700	8.0	9.0	8.0	9.0	8.0	9.0
Algeria	2115	23.5	17.5	74.5	235	1750	8.2	9.2	8.2	9.2	8.2	9.2
Algeria	2120	24.0	18.0	75.0	240	1800	8.5	9.5	8.5	9.5	8.5	9.5
Algeria	2125	24.5	18.5	75.5	245	1850	8.8	9.8	8.8	9.8	8.8	9.8
Algeria	2130	25.0	19.0	76.0	250	1900	9.0	10.0	9.0			

PI JP 2003206238 A2 20030722 JP 2002-322064 20021106

PRAI JP 2001-340345 A 20011106

L8 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AB The products and methods of the present invention provide a means for increasing the soly. and bioavailability of active agents. More particularly the invention provides compns. contg. active agents as

water-sol. complexes with glycyrrhizin, and methods of prepg. such complexes. The invention further provides methods for the prepn. of highly water-sol. complex dosage forms. Monoammonium glycyrrhizin 27 g and 33 g famotidine were dissolved in 1140 g 50% EtOH-H2O mixt. The resulting soln. was then spray-dried to obtain famotidine/glycyrrhizin complex powder. The complex powder (30 g) was blended with 1 g cherry flavor powder, 1 g acesulfame potassium and 44 g sorbitol. The resulting powder, 92 mg as a unit wt., was filled in the water sol. and edible film sachet which was prepd. from 10 mg propylene glycol and 50 mg HPMC. The resulting sachet, which contains 20 mg famotidine, could be directly dropped into water to reconstitute the aq. soln. or taken orally with or without drinking any water.

AN 2002:736055 CAPLUS
 DN 137:253008
 TI Water-soluble and palatable complexes
 IN Chen, Li-Lan H.; Tao, Li; Liang, Alfred
 PA Lavipharm Laboratories Inc., USA
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074238	A2	20020926	WO 2002-US3816	20020208
	WO 2002074238	A3	20030410		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002147201	A1	20021010	US 2002-71380	20020208
PRAI	US 2001-269785P	P	20010216		

L8 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
 AB Compns. for pharmaceutical and other uses comprise clear aq. solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aq. soln. The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aq. sol. starch conversion product and an aq. sol. non-starch polysaccharide. The compn. remains in soln. without forming a ppt. over a range of pH values and, according to one embodiment, remains in soln. for all pH values obtainable in an aq. system. The compn. may further contain a pharmaceutical compd., such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, soln. dosage forms that did not show any pptn. at any pH were prepd. contg. ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

AN 2002:185616 CAPLUS
 DN 136:252482
 TI Preparation of aqueous clear solution dosage forms with bile acids
 IN Yoo, Seo Hong
 PA USA
 SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 3

7 applicant

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002031558	A1	20020314	US 2001-778154	20010205
	US 6251428	B1	20010626	US 1999-357549	19990720
PRAI	US 1998-94069P	P	19980724		
	US 1999-357549	A2	19990720		
	US 2000-180268P	P	20000204		

L8 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
 AB A method of making antacid coated chewing gum products comprises the steps of providing chewing gum cores, a coating syrup comprising a bulk sweetener, calcium carbonate and a binding agent; and applying the coating syrup to the cores and drying the syrup to produce a sugarless coating on the cores. The coating on the cores produces a high viscosity in saliva when the gum is chewed, in that 4.5 g of the coating dispersed in 30 mL of water has a Brookfield viscosity at 23.degree. of at least 1.6 cP. Thus, a formulation contained gum base 30.0, CaCO3 5.0, sorbitol 46.0, mannitol 5.0, glycerin 2.0, sorbitol liq. 10.0, flavor 1.5, and encapsulated high-intensity sweetener 0.5%.

AN 2002:171730 CAPLUS
 DN 136:221736
 TI Antacid chewing gum products coated with high viscosity materials
 IN Zyck, Daniel; Greenberg, Michael J.; Barkalow, David G.; Marske, Scott W.; Urnezis, Philip G.; Mazzone, Philip
 PA Wm. Wrigley Jr. Company, USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002017966	A1	20020307	WO 2001-US27341	20010831
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001088669	A5	20020313	AU 2001-88669	20010831
PRAI	US 2000-653669	A	20000901		
	WO 2001-US27341	W	20010831		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
 AB A method of making coated chewing gum products contg. an acid blocker, comprises the steps of providing chewing gum cores; providing a coating syrup comprising a bulk sweetener; providing an acid blocker; applying the coating syrup and acid blocker to the cores; and drying the syrup to produce a coating on the cores, the coating contg. the acid blocker. The acid blockers include histamine H2 receptor antagonists selected from the group consisting of cimetidine, famotidine, ranitidine, nizatidine and salts thereof and gastric proton pump inhibitors selected from the group consisting of omeprazole, rabeprazole, and combinations thereof.

AN 2001:677207 CAPLUS
 DN 135:216035
 TI Coated chewing gum products containing an acid blocker
 IN Zyck, Daniel J.; Greenberg, Michael J.; Barkalow, David G.; Marske, Scott W.; Schnell, Philip G.; Mazzone, Philip; Witkewitz, David L.
 PA Zyck, Daniel, USA
 SO U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 552,290.

CODEN: USXXCO

DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001021373	A1	20010913	US 2000-748699	20001222
	US 6541048	B2	20030401		
	US 6472000	B1	20021029	US 1999-319054	19990526
	US 6586023	B1	20030701	US 2000-552290	20000419
	WO 2002056699	A1	20020725	WO 2001-US48066	20011214
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-389211	B1	19990902		
	US 2000-552290	A2	20000419		
	WO 1996-US18977	A2	19961127		
	WO 1996-US20252	W	19961223		
	US 1998-112389P	P	19981215		
	US 1999-308972	A2	19990527		
	US 2000-748699	A	20001222		

L8 ANSWER 6 OF 10 USPATFULL on STN

AB The products and methods of the present invention provide a means for increasing the solubility and bioavailability of active agents. More particularly the invention provides compositions containing active agents as water-soluble complexes with glycyrrhizin, and methods of preparing such complexes. The invention further provides methods for the preparation of highly water soluble complex dosage forms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:266322 USPATFULL
TI Water soluble and palatable complexes
IN Chen, Li-Lan H., Edison, NJ, UNITED STATES
Tao, Li, Edison, NJ, UNITED STATES
Liang, Alfred, Edison, NJ, UNITED STATES
PA Lavipharm Laboratories Inc. (U.S. corporation)
PI US 2002147201 A1 20021010
AI US 2002-71380 A1 20020208 (10)
PRAI US 2001-269785P 20010216 (60)
DT Utility
FS APPLICATION
LREP ALLEN BLOOM, C/O DECHERT, PRINCETON PIKE CORPORATION CENTER, P.O. BOX 5218, PRINCETON, NJ, 08543-5218
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 10 USPATFULL on STN

AB Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without

forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further contain a pharmaceutical compound in a pharmaceutically effective amount. Non-limiting examples of pharmaceutical compounds include insulin, heparin, bismuth compounds, amantadine and rimantadine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:54399 USPATFULL
TI Preparation of aqueous clear solution dosage forms with bile acids
IN Yoo, Seo Hong, Wyckoff, NJ, UNITED STATES
PI US 2002031558 A1 20020314
AI US 2001-778154 A1 20010205 (9)
RLI Continuation-in-part of Ser. No. US 1999-357549, filed on 20 Jul 1999, GRANTED, Pat. No. US 6251428
PRAI US 1998-94069P 19980724 (60)
US 2000-180268P 20000204 (60)
DT Utility
FS APPLICATION
LREP BAKER BOTTS L.L.P., 44TH FLOOR, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112-4498
CLMN Number of Claims: 87
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 10 USPATFULL on STN

AB Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:50631 USPATFULL
TI Over-coated chewing gum formulations
IN Ream, Ronald L., Plano, IL, United States
Greenberg, Michael J., Northbrook, IL, United States
Wokas, William J., Bolingbrook, IL, United States
Corriveau, Christine L., Orland Park, IL, United States
PA Wm. Wrigley Jr. Company, Chicago, IL, United States (U.S. corporation)
PI US 6355265 B1 20020312
AI US 2000-510878 20000223 (9)
RLI Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999
Continuation-in-part of Ser. No. WO 1999-US29742, filed on 14 Dec 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Howard, S.
LREP Bell, Boyd & Lloyd LLC
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1508

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 10 USPATFULL on STN

AB A method of making coated chewing gum products containing an acid

blocker comprises the steps of providing chewing gum cores; providing a coating syrup comprising a bulk sweetener, providing an acid blocker, applying the coating syrup and acid blocker to the cores and drying the syrup to produce a coating on the cores, the coating containing the acid blocker.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:155442 USPATFULL
TI Coated chewing gum products containing an acid blocker
IN Zyck, Daniel J., North Riverside, IL, United States
Greenberg, Michael J., Northbrook, IL, United States
Barkalow, David G., Deerfield, IL, United States
Marske, Scott W., LaGrange, IL, United States
Schnell, Philip G., Downers Grove, IL, United States
Mazzone, Philip, Griffith, IN, United States
Witkewitz, David L., Bridgeview, IL, United States
PI US 2001021373 A1 20010913
US 6541048 B2 20030401
AI US 2000-748699 A1 20001222 (9)
RLI Continuation-in-part of Ser. No. US 2000-552290, filed on 19 Apr 2000,
PENDING Continuation of Ser. No. US 1999-389211, filed on 2 Sep 1999,
ABANDONED
DT Utility
FS APPLICATION
LREP BRINKS HOFER GILSON & LIONE, P.O. BOX 10395, CHICAGO, IL, 60610
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1018
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 10 EUROPATFULL COPYRIGHT 2003 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1336408 EUROPATFULL ED 20030825 EW 200334 FS OS
TIEN WATER-SOLUBLE LIQUID INTERNAL MEDICINE.
TIDE WASSERLOESLICHES FLUESSIGES MEDIKAMENT ZUR EINNAHME.
TIFR LIQUIDE HYDROSOLUBLE POUR MEDECINE INTERNE.
IN HASHIMOTO, Yoshimi, c/o Yamanouchi Pharmaceutical Co., Ltd., 17-1,
Hasune 3-chome, Itabashi-ku, Tokyo, JP;
FURUYA, Nobuyoshi, c/o Yamanouchi Pharmaceutical Co., Ltd., 180, Ozumi,
Yaizu-shi, Shizuoka 425-0072, JP;
KOJIMA, Haruyoshi, c/o Yamanouchi Pharmaceutical Co., Ltd., 180, Ozumi,
Yaizu-shi, Shizuoka 425-0072, JP
PA YAMANOUCHI PHARMACEUTICAL CO. LTD., No. 3-11 Nihonbashi-Honcho, 2-chome
Chuo-ku, Tokyo 103-8411, JP
PAN 274784
AG Bates, Philip Ian, Reddie & Grose 16 Theobalds Road, London WC1X 8PL, GB
AGN 98181
OS MEPA2003063 EP 1336408 A1 0009
SO Wila-EPZ-2003-H34-T1b
DT Patent
LA Anmeldung in Japanisch; Veroeffentlichung in Englisch;
Verfahren in Englisch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE;
R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK;
R RO; R SI
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PI EP 1336408 A1 20030820
OD 20030820
AI EP 2001-997305 20011121
PRAI JP 2000-2000357701 20001124
RLI WO 01-JP10175 011121 INTAKZ

WO 02041892

020530 INTPNR